Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Future ETFs Channel
  2. Tech Could Lead Next Wave of Healthcare Evolution
Future ETFs Channel
Share

Tech Could Lead Next Wave of Healthcare Evolution

Tom LydonJun 15, 2022
2022-06-15

There’s an emerging intersection between healthcare and technology, with the former’s evolution largely dependent on the latter.

For investors who want exposure to that theme without the burden of stock-picking, some exchange traded funds are levered to the intersection of healthcare and technology. However, this is an arena where selectivity matters, and active management can offer benefits.

Enter the Goldman Sachs Future Health Care Equity ETF (GDOC). GDOC, which debuted last November, could prove to be at the right place at the right time for long term-minded healthcare investors looking to capitalize on the next wave of tech-driven growth in this sector.

“We are now at a critical inflection point. Rapidly accelerating innovation is doing more than delivering vaccines in record time. It is reshaping the entire health care industry. Over the last few decades, cost curves have declined dramatically and groundbreaking new treatments have become commercially scalable, prompting the industry to change how it treats patients by shifting the focus from reactive to preventive medicine,” noted Goldman Sachs Asset Management (GSAM).

GDOC holds 55 stocks, and while funds of this nature are usually concentrated, active management allows GDOC to spread its wings a bit. The Goldman Sachs ETF features exposure to basic biotechnology and pharmaceuticals companies as well as growthier genomics an medical devices names, among others.

That expanse levers GDOC to compelling themes with attractive long-term runways such as digital health and precision, just to name a pair.

“At the convergence of data science and lab science lies precision medicine, the development of personalized treatments and therapies based on a patient’s genetic makeup or other molecular or cellular analysis,” added GSAM. "Precision medicine can expand the horizon of available therapies for patients, such as targeted oncology and gene and cell therapy. This has important implications for the treatment of rare diseases, which afflict roughly 30 million people in the United States alone.”

Another area of the GDOC roster with long-term potential is genomics. Those names are out of favor today due to the growth stock slump, but amid declining costs, the future is bright for this corner of the healthcare sector.

“When the first human genome was sequenced in 1999, the process took roughly four years and cost an estimated $0.5 billion. Today, it costs around $600 and can be completed in as little as one day,” concluded GSAM. “Genomics—the science of reading, analyzing and editing genomes—has seen rapid expansion and development since its early days. This creates an opportunity to expand our knowledge about new treatments and cures.”

For more news, information, and strategy, visit the Future ETFs Channel.

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X